Clinical Trial

Phase 1/2 Study of UI-102 in Selected Advanced Cancers

Name: Phase 1/2 Study of UI-102 in Selected Advanced Cancers — clinical trial record (NCT07605962)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This phase 1/2 first-in-human study is designed to assess the safety and efficacy of UI-102, a TLR7/8 agonist encapsulated in a Cholesteryl Pullulan Nanoparticle.

Protocol Amendment History 1 change

critical Recruitment opened 2026-06-04

Trial Details

NCT Number	NCT07605962
Lead Sponsor	United Immunity, co., Ltd.
Conditions	Advanced Cancer
Enrollment	140 participants
Start Date	2026-05-20
Primary Completion	2030-03-31 (estimated)
Study Completion	2031-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-03